guest ::
| Home > Publications database > Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study. |
| Home > Publications database > Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study. |
| Journal Article | DKFZ-2023-00703 |
; ; ; ; ; ; ; ; ; ; ; ; ; ;
2023
Soc.
New York, NY
This record in other databases: 
Please use a persistent id in citations: doi:10.2967/jnumed.122.264456
Abstract: The radium lutetium (RALU) study evaluated the feasibility of sequential α- and β-emitter use in patients with bone-predominant metastatic castration-resistant prostate cancer. Methods: This preplanned interim retrospective analysis investigated safety and survival outcomes with 177Lu-PSMA in patients treated with prior 223Ra. Results: Forty-nine patients were evaluated. Patients received a median of 6 223Ra injections; 59% of patients received at least 4 177Lu-PSMA cycles. Most (69%) patients received at least 4 life-prolonging therapies before 177Lu-PSMA. Common Terminology Criteria for Adverse Events grade 3-4 treatment-emergent adverse events during 177Lu-PSMA therapy and a 30-d follow-up period included anemia (18%) and thrombocytopenia (2%). Median overall survival was 12.6 mo (95% CI, 8.8-16.1 mo) and 31.4 mo (95% CI, 25.7-37.6 mo) from starting 177Lu-PSMA or 223Ra, respectively. Conclusion: 177Lu-PSMA treatment was well tolerated in patients who had received prior 223Ra. 223Ra use before 177Lu-PSMA is feasible and can be considered for future assessment of the optimal treatment sequence.
Keyword(s): Male (MeSH) ; Humans (MeSH) ; Lutetium: adverse effects (MeSH) ; Radium: adverse effects (MeSH) ; Prostatic Neoplasms, Castration-Resistant (MeSH) ; Treatment Outcome (MeSH) ; Retrospective Studies (MeSH) ; Prostate: pathology (MeSH) ; Prostate-Specific Antigen (MeSH) ; Dipeptides: adverse effects (MeSH) ; Heterocyclic Compounds, 1-Ring: adverse effects (MeSH) ; 177Lu-PSMA ; 223Ra ; metastatic castration-resistant prostate cancer ; real-world practice ; targeted α-therapy ; Lutetium ; Radium ; Prostate-Specific Antigen ; Dipeptides ; Heterocyclic Compounds, 1-Ring
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Essential Science Indicators ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
